Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy...

por Conte, PierFranco, Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., von Minckwitz, Gunter, Mano, Max S., Untch, Michael, Huang, Chiun‐Sheng, Wolmark, Norman, Rastogi, Priya, D’Hondt, Veronique, Redondo, Andrés, Stamatovic, Ljiljana, Bonnefoi, Hervé, Castro‐Salguero, Hugo, Fischer, Hans H., Wahl, Tanya, Song, Chunyan, Boulet, Thomas, Trask, Peter, Geyer, Charles E.
Publicado 2020

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

por Liao, John B, Gwin, William R, Urban, Renata R, Hitchcock-Bernhardt, Katie M, Coveler, Andrew L, Higgins, Doreen M, Childs, Jennifer S, Shakalia, Hania N, Swensen, Ron E, Stanton, Sasha E, Tinker, Anna V, Wahl, Tanya A, Ancheta, Richard G, McGonigle, Kathryn F, Dai, James Y, Disis, Mary L, Goff, Barbara A
Publicado 2021